Ursodeoxycholic acid for bilirubin in acute viral hepatitis
Treatments studied
Part of Digestive system, Infections clinical trials.
This trial tests whether an oral medication called ursodeoxycholic acid can help lower bilirubin levels in people with acute viral hepatitis. Lower bilirubin may help reduce jaundice and improve liver recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 50 years old.
- You must have acute viral hepatitis (a sudden liver inflammation caused by a virus).
- Your bilirubin levels (a yellow pigment that causes jaundice) must be high.
- You cannot have chronic Hepatitis B or C.
- You cannot have liver cancer, primary biliary cholangitis (a bile duct disease), or gallstones in the bile duct.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether slowly reducing UDCA (a medication for primary biliary cholangitis) is safe and still helpful in people whose liver tests have improved. It may help some patients avoid higher doses if their disease is well controlled.
This trial tests whether ursodeoxycholic acid (a bile medicine) can help prevent complications from gallstone-related acute pancreatitis from coming back after you leave the hospital. It may help reduce repeat problems linked to gallstones, especially after an initial pancreatitis episode.
This study tests a medication called obeticholic acid to see if it improves liver fat and blood flow in people who have chronic hepatitis B and fatty liver. If you qualify, you may receive this treatment and be monitored with ultrasound and liver scans.
This trial tests whether adding ursodeoxycholic acid (a bile acid supplement) to standard sepsis treatment can reduce inflammation and organ damage. It aims to improve recovery in adults with sepsis.
This study tests whether taking ursodeoxycholic acid (a bile acid pill) after a living donor liver transplant helps the new liver grow and work better. It may speed up recovery and improve liver function.
This trial tests adding prednisone (a steroid) to ursodeoxycholic acid (a bile acid medicine) for people with primary biliary cholangitis who have a specific type of liver inflammation. The goal is to see if the combination works better at controlling the disease than standard care.
Hear when a new Hepatitis A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.